Janux Therapeutics, Inc.
NASDAQ:JANXBiotechnology
Healthcare
$10.29 -1.74%
-$0.25 today
- Market cap
- $629.58M
- Beta
- 2.52
- P/E (TTM)
- -7.6
- EPS (TTM)
- -$1.83
52W Low $12.12High $35.34
Volume 0.65M
Average 1.02M
Income Statement
Follow revenue through to earnings.
Revenue
$10.00M
FY 2025 · Annual
-5.6% YoYOperating Income
-$157.67M
FY 2025 · Annual
Net Income
-$113.63M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 3.64M | 8.61M | 8.08M | 10.59M | 10M |
| Cost of Revenue | 26.24M | 841K | 1.96M | 2.06M | 2.03M |
| Gross Profit | (22.6M) | 7.77M | 6.13M | 8.53M | 7.97M |
| Gross Margin | -621.4% | 90.2% | 75.8% | 80.5% | 79.7% |
| Research & Development | 26.24M | 53.44M | 54.92M | 68.39M | 125.9M |
| Selling, General & Admin | 10.33M | 22.26M | 26.14M | 41.05M | 41.77M |
| Operating Expenses | 10.33M | 74.86M | 79.11M | 107.38M | 165.64M |
| Depreciation & Amortization | 113K | 841K | 1.96M | 2.06M | 2.03M |
| EBITDA | (32.56M) | (62.22M) | (56.34M) | (66.93M) | (111.6M) |
| EBITDA Margin | -895.2% | -722.5% | -697.0% | -632.2% | -1116.0% |
| Operating Income | (32.93M) | (67.09M) | (72.98M) | (98.85M) | (157.67M) |
| Operating Margin | -905.4% | -779.0% | -902.9% | -933.6% | -1576.7% |
| Interest Income | 257K | 4.03M | 14.69M | 29.85M | 44.04M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 257K | 4.03M | 14.69M | 29.85M | 44.04M |
| Income Before Tax | (32.67M) | (63.06M) | (58.29M) | (68.99M) | (113.63M) |
| Pre-Tax Margin | -898.3% | -732.2% | -721.2% | -651.6% | -1136.3% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (32.67M) | (63.06M) | (58.29M) | (68.99M) | (113.63M) |
| Net Margin | -898.3% | -732.2% | -721.2% | -651.6% | -1136.3% |
| EPS (Basic) | (0.79) | (1.52) | (1.32) | (1.28) | (1.83) |
| EPS (Diluted) | (0.79) | (1.52) | (1.32) | (1.28) | (1.83) |
| 41.24M | 41.47M | 44.02M | 53.75M | 61.97M | |
| 41.24M | 41.47M | 44.02M | 53.75M | 61.97M |
JANX Earnings Waterfall · TTM
NASDAQ:JANX · Revenue to Net Income
Key Ratios
EPS$-1.84
Gross Margin42.2%
Net Margin-325.3%
P/E Ratio-10.4
P/S Ratio123.4
Analysis
$21.6M of revenue converted into -$114.5M of net income for the selected period. Gross margin is 42.2% and net margin is -325.3%, showing how much revenue survives after costs and taxes. EPS is $-1.84, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G/A | SC 13G/A filing | Nov 13, 2026 | |
| 8-K | Current report | Nov 5, 2026 | |
| 10-Q | Quarterly report | Nov 5, 2026 | |
| SC 13G/A | SC 13G/A filing | Aug 14, 2026 | |
| SC 13G/A | SC 13G/A filing | Aug 13, 2026 |
How much revenue does JANX generate?
Janux Therapeutics, Inc. (JANX) reported $10.00M of revenue in fiscal 2025.
Is JANX profitable?
Janux Therapeutics, Inc. (JANX) reported -$113.63M of net income, with a net margin of -1136.3%.
Continue the stock analysis
Jump to another research area for this company.